Galectin-4, a novel predictor for lymph node metastasis in lung adenocarcinoma

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Hayashi, Takuo ^a   Saito, Tsuyoshi ^a   Fujimura, Tsutomu ^b   Hara, Kieko ^a   Takamochi, Kazuya ^b   Mitani, Keiko ^a   Mineki, Reiko ^b   Kazuno, Saiko ^b   Oh, Shiaki ^b   Ueno, Takashi ^b   Suzuki, Kenji ^b   Yao, Takashi ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 4;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MIDDLE AGED; POLYACRYLAMIDE GEL ELECTROPHORESIS; SURVIVAL PREDICTION; TUMOR INVASION; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GALECTIN 4; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RETROSPECTIVE STUDIES;

EID: 84892428971     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081883     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
3. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-500.
4. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
5. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-6.
6. Scagliotti GV, Pastorino U, Vansteenkiste JF, Spaggiari L, Facciolo F, et al. (2012) Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol 30: 172-178.
7. Jan YH, Tsai HY, Yang CJ, Huang MS, Yang YF, et al. (2012) Adenylate kinase-4 is a marker of poor clinical outcomes that promotes metastasis of lung cancer by downregulating the transcription factor ATF3. Cancer research 72:5119-29.
8. Liu YF, Xiao ZQ, Li MX, Li MY, Zhang PF, et al. (2009) Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol 217:54-64.
9. Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, et al. (2002) Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 161:1647-56.
10. Su JL, Yang CY, Shih JY, Wei LH, Hsieh CY, et al. (2006) Knockdown of contactin-1 expression suppresses invasion and metastasis of lung adenocarcinoma. Cancer research 66:2553-61.
11. Chang CC, Shih JY, Jeng YM, Su JL, Lin BZ, et al. (2004) Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst 96:364-75.
12. Shih JY, Yang SC, Hong TM, Yuan A, Chen JJ, et al. (2001) Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells. J Natl Cancer Inst 93:1392-400.
13. Zhang PF, Zeng GQ, Hu R, Li C, Yi H, et al. (2012) Identification of Flotillin-1 as a novel biomarker for lymph node metastasis and prognosis of lung adenocarcinoma by quantitative plasma membrane proteome analysis. J Proteomics 77:202-14.
14. Mitsuta K, Yokoyama A, Kondo K, Nakajima M, Arita K, et al. (2005). Polymorphism of the MUC1 mucin gene is associated with susceptibility to lung adenocarcinoma and poor prognosis. Oncol Rep 14:185-9.
15. Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, et al. (2000) Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 6:2431-9.
16. Shih JY, Tsai MF, Chang TH, Chang YL, Yuan A, et al. (2005) Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res 11:8070-8.
17. Creighton CJ, Bromberg-White JL, Misek DE, Monsma DJ, Brichory F, et al. (2005) Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation. Mol Cancer Res 3:119-29.
18. Shibata T, Uryu S, Kokubu A, Hosoda F, Ohki M, et al. (2005) Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. Clin Cancer Res 11:6177-85.
19. Nakamura N, Kobayashi K, Nakamoto M, Kohno T, Sasaki H, et al. (2006) Identification of tumor markers and differentiation markers for molecular diagnosis of lung adenocarcinoma. Oncogene 25:4245-55.
20. Larsen JE, Pavey SJ, Passmore LH, Bowman RV, Hayward NK, et al. (2007) Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 13:2946-54.
21. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (2004) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon 2004.
22. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, et al. (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol, 6:244-85.
23. Saito S, Murayama Y, Pan Y, Taima T, Fujimura T, et al. (2008) Haptoglobinbeta chain defined by monoclonal antibody RM2 as a novel serum marker for prostate cancer. Int J Cancer 123:633-40.
24. Fujimura T, Shinohara Y, Tissot B, Pang PC, Kurogochi M, et al. (2008) Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects. Int J Cancer, 122:39-49.
25. Kazuno S, Fujimura T, Arai T, Ueno T, Nagao K, et al. (2011) Multi-sequential surface plasmon resonance analysis of haptoglobin-lectin complex in sera of patients with malignant and benign prostate diseases. Anal Biochem, 419:241-9.
26. Horie A, Tomita T, Saiki A, Kono H, Taka H, et al. (2009) Discovery of proteinaceous N-modification in lysine biosynthesis of Thermus thermophilus. Nat Chem Biol 5:673-9.
27. Newlaczyl AU, Yu LG (2011) Galectin-3 - a jack-of-all-trades in cancer. Cancer Lett 313:123-8.
28. Barondes SH, Cooper DN, Gitt MA, Leffler H (1994) Galectins. Structure and function of a large family of animal lectins. J Biol Chem 269:20807-10.
29. Cooper DN (2002) Galectinomics: finding themes in complexity. Biochim Biophys Acta 1572:209-31.
30. Leffler H, Carlsson S, Hedlund M, Qian Y, Poirier F (2004) Introduction to galectins. Glycoconj J 19:433-40.
31. Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C (2002) Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 23:313-20.
32. Huflejt ME, Leffler H (2004) Galectin-4 in normal tissues and cancer. Glycoconj J 20:247-55.
33. Shen HM, Tergaonkar V (2009) NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 14:348-63.
34. Kondoh N, Wakatsuki T, Ryo A, Hada A, Aihara T, et al. (1999) Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer research 59:4990-6.
35. Hippo Y, Yashiro M, Ishii M, Taniguchi H, Tsutsumi S, et al. (2001) Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer research 61:889-95.
36. Satelli A, Rao PS, Thirumala S, Rao US (2011) Galectin-4 functions as a tumor suppressor of human colorectal cancer. Int J Cancer 129:799-809.
37. Nakahara S, Raz A (2007) Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway. Cancer Metastasis Rev 26:605-10.
38. Warth A, Muley T, Meister M, Stenzinger A, Thomas M, et al. (2012) The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 30:1438-46.
39. Hughes RC (1999) Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta 1473:172-85.
40. Barrow H, Guo X, Wandall HH, Pedersen JW, Fu B, et al. (2011) Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res 17:7035-46.
41. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, et al. (2000) Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 6:1389-93.
42. Watanabe M, Takemasa I, Kaneko N, Yokoyama Y, Matsuo E, et al. (2011) Clinical significance of circulating galectins as colorectal cancer markers. Oncol Rep 25:1217-26.
43. Chen G, Gharib TG, Wang H, Huang CC, Kuick R, et al. (2003) Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A 100:13537-42.